Cargando…

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis

OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yen Chih, Winokur, Paige, Blake, Andrew, Wu, Tianxia, Romm, Elena, Bielekova, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435700/ https://www.ncbi.nlm.nih.gov/pubmed/26000318 http://dx.doi.org/10.1002/acn3.181

Ejemplares similares

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
por: Stein, Jason, et al.
Publicado: (2018)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis
por: Wuest, Simone C., et al.
Publicado: (2014)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation
por: Bielekova, Bibiana, et al.
Publicado: (2012)

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
por: Masvekar, Ruturaj, et al.
Publicado: (2021)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes
por: Natrajan, Muktha S., et al.
Publicado: (2015)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Biomarkers in Multiple Sclerosis
por: Martin, Roland, et al.
Publicado: (2006)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy
por: Wuest, Simone C., et al.
Publicado: (2011)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Publicado: (2021)

Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis
por: Liu, Joshua, et al.
Publicado: (2022)

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment
por: Kosa, Peter, et al.
Publicado: (2016)

Confounder-adjusted MRI-based predictors of multiple sclerosis disability
por: Kim, Yujin, et al.
Publicado: (2022)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis
por: Masvekar, Ruturaj, et al.
Publicado: (2019)

Intrathecal Inflammation in Progressive Multiple Sclerosis
por: Monaco, Salvatore, et al.
Publicado: (2020)

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
por: Weideman, Ann Marie, et al.
Publicado: (2017)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping
por: Hannikainen, Paavali A., et al.
Publicado: (2020)

Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis
por: Tanigawa, Makoto, et al.
Publicado: (2017)

Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms
por: Kosa, Peter, et al.
Publicado: (2022)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis
por: Pham, Linh, et al.
Publicado: (2021)

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2019)

Intrathecal, Polyspecific Antiviral Immune Response in Oligoclonal Band Negative Multiple Sclerosis
por: Brecht, Isabel, et al.
Publicado: (2012)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

Intrathecal T‐cell clonal expansions in patients with multiple sclerosis
por: de Paula Alves Sousa, Alessandra, et al.
Publicado: (2016)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis
por: DiSano, Krista D, et al.
Publicado: (2020)

High prevalence of intrathecal IgA synthesis in multiple sclerosis patients
por: Muñoz, Úrsula, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1mpeg5r8bjkpck817po97clnd4